Our top pick for
CRH plc is a building materials business based in the US. CRH shares (CRH) are listed on the NYSE and all prices are listed in US Dollars. CRH employs 77,100 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$47.71|
|52-week range||$32.76 - $53.75|
|50-day moving average||$49.59|
|200-day moving average||$50.01|
|Wall St. target price||$24.01|
|Dividend yield||$1.16 (2.46%)|
|Earnings per share (TTM)||$1.90|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||1.10%|
|1 month (2021-09-21)||-3.13%|
|3 months (2021-07-21)||-2.33%|
|6 months (2021-04-21)||-0.65%|
|1 year (2020-10-21)||27.02%|
|2 years (2019-10-21)||35.19%|
|3 years (2018-10-19)||68.59%|
|5 years (2016-10-21)||44.14%|
Valuing CRH stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRH's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CRH's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, CRH shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
CRH's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3157. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CRH's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
CRH's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.3 billion.
The EBITDA is a measure of a CRH's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$29.4 billion|
|Operating margin TTM||9.83%|
|Gross profit TTM||$9.4 billion|
|Return on assets TTM||3.91%|
|Return on equity TTM||8.07%|
|Market capitalisation||$36.9 billion|
TTM: trailing 12 months
There are currently 1.2 million CRH shares held short by investors – that's known as CRH's "short interest". This figure is 21% up from 982,617 last month.
There are a few different ways that this level of interest in shorting CRH shares can be evaluated.
CRH's "short interest ratio" (SIR) is the quantity of CRH shares currently shorted divided by the average quantity of CRH shares traded daily (recently around 519217.90393013). CRH's SIR currently stands at 2.29. In other words for every 100,000 CRH shares traded daily on the market, roughly 2290 shares are currently held short.
However CRH's short interest can also be evaluated against the total number of CRH shares, or, against the total number of tradable CRH shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CRH's short interest could be expressed as 0% of the outstanding shares (for every 100,000 CRH shares in existence, roughly 0 shares are currently held short) or 0.0015% of the tradable shares (for every 100,000 tradable CRH shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CRH.
Find out more about how you can short CRH stock.
Dividend payout ratio: 79.83% of net profits
Recently CRH has paid out, on average, around 79.83% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.46% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CRH shareholders could enjoy a 2.46% return on their shares, in the form of dividend payments. In CRH's case, that would currently equate to about $1.16 per share.
CRH's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
CRH's most recent dividend payout was on 14 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 8 September 2021 (the "ex-dividend date").
CRH's shares were split on a 5:1 basis on 23 August 1998. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your CRH shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for CRH shares which in turn could have impacted CRH's share price.
Over the last 12 months, CRH's shares have ranged in value from as little as $32.7592 up to $53.7485. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CRH's is 0.9257. This would suggest that CRH's shares are less volatile than average (for this exchange).
CRH plc, through its subsidiaries, manufactures and distributes building materials. It operates in three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, kerbs, retaining walls, and related patio products; and glass and glazing products, including architectural glass, custom-engineered curtain and window walls, architectural windows, storefront systems, doors, skylights, and architectural hardware. It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. It serves governments, contractors, homebuilders, homeowners, and sub-contractors.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.